Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

181. Functional connectivity in Idiopathic Generalised Epilepsies: A systematic review and meta-analysis

Functional connectivity in Idiopathic Generalised Epilepsies: A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

182. Systematic review of epidemiological studies and management of epilepsy in disorders of consciousness

Systematic review of epidemiological studies and management of epilepsy in disorders of consciousness Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

183. An evidence map of antiepileptic drugs for epilepsy

An evidence map of antiepileptic drugs for epilepsy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect

2017 PROSPERO

184. Correlates and consequences of internalised stigma for people living with epilepsy

Correlates and consequences of internalised stigma for people living with epilepsy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

185. Seizure resolution and complications following management of epilepsy associated with hypothalamic hamartoma: a systematic review

Seizure resolution and complications following management of epilepsy associated with hypothalamic hamartoma: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

186. The accuracy and utility of using administrative healthcare databases to identify people with epilepsy: protocol for a systematic review and meta-analysis

The accuracy and utility of using administrative healthcare databases to identify people with epilepsy: protocol for a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2017 PROSPERO

187. The burden of epilepsy in India: an epidemiological review

The burden of epilepsy in India: an epidemiological review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2017 PROSPERO

188. Gabapentin monotherapy for epilepsy [Cochrane protocol]

Gabapentin monotherapy for epilepsy [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2017 PROSPERO

189. Oxcarbazepine add-on for drug-resistant partial epilepsy [Cochrane protocol]

Oxcarbazepine add-on for drug-resistant partial epilepsy [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

190. Oxcarbazepine add-on for drug-resistant partial epilepsy [Cochrane Protocol]

Oxcarbazepine add-on for drug-resistant partial epilepsy [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2017 PROSPERO

191. Perampanel monotherapy for epilepsy [Cochrane protocol]

Perampanel monotherapy for epilepsy [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2017 PROSPERO

192. Perampanel monotherapy for epilepsy [Cochrane Protocol]

Perampanel monotherapy for epilepsy [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2017 PROSPERO

193. Depression and anxiety in children and adolescents with epilepsy: a systematic review and meta-analysis

Depression and anxiety in children and adolescents with epilepsy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

194. Anti-epileptics for juvenile myoclonic epilepsy: a network meta-analysis of randomized clinical trials and cohort studies

Anti-epileptics for juvenile myoclonic epilepsy: a network meta-analysis of randomized clinical trials and cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

195. Epilepsy in childhood and the risk of autism spectrum disorder: a systematic review and meta-analysis

Epilepsy in childhood and the risk of autism spectrum disorder: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2017 PROSPERO

196. Cannabis and cannabinoids for medical purposes: a systematic review for the treatment of epilepsy

Cannabis and cannabinoids for medical purposes: a systematic review for the treatment of epilepsy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

197. Working memory in epilepsy: a systematic review and meta-analysis

Working memory in epilepsy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2017 PROSPERO

198. Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients

Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Intravenous immunoglobulin (...) for treatment of intractable epilepsy in pediatric patients. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Health Problem: Intractable epilepsy is diagnosed in 5% to 20% of pediatric patients with new-onset epilepsy. If uncontrolled, seizures in childhood may have a detrimental or even catastrophic impact on the developing brain. A connection has been made between inflammatory processes and neurological disease, including epilepsy, which may present new therapeutic

2017 Health Technology Assessment (HTA) Database.